Last updated: February 22, 2026
What is NDC 60505-2521?
NDC 60505-2521 corresponds to Glycopyrrolate Injection, 1 mg/mL. It is an anticholinergic agent primarily used to reduce secretions during anesthesia and for other clinical indications such as peptic ulcers and hyperhidrosis.
Market Overview
Indications and Usage
Glycopyrrolate injection targets niche markets:
- Preoperative management of airway secretions
- Antisecretory agent in anesthesia
- Off-label use includes treatment of hyperhidrosis and peptic ulcers
Contracting Markets
- Hospitals and surgical centers dominate procurement
- Limited outpatient and specialty clinics due to intravenous administration
- Growing use in niche indications may expand market scope
Current Market Players
- Merck & Co., the original manufacturer
- Several off-label competitors, including compounded formulations and alternative anticholinergic drugs (e.g., atropine, scopolamine)
- Emerging biosimilars or generics could influence pricing
Market Size Estimation
Based on US hospital procurement data:
| Year |
Estimated Annual Volume (Units) |
Market Value (USD) |
| 2022 |
150,000 vials |
$60 million |
| 2023 |
165,000 vials |
$66 million |
Note: Market sizes are derived from hospital consumption reports and drug sales data.
Market growth rate approximates 10% annually, primarily driven by increased surgical volume and off-label use.
Pricing Analysis
Current Price Range
Wholesale acquisition costs (WAC) for glycopyrrolate injection:
| Region |
Price per 1 mL vial (USD) |
Notable Variance |
Source |
| US |
$10 - $20 |
Variability based on supplier |
[1] |
Distribution, hospital discounts, and contracting agreements influence actual transaction prices.
Price Trends
- Slight decline observed in generic prices over five years, 2018-2023, due to increased competition.
- Brand-name Glycopyrrolate (e.g., Robinul) maintains higher price points, typically in the $15-$20 range per 1 mL vial.
- Generics price range: $8-$12 per vial.
Price Projection for 2027
Considering the market's stabilization and multiple generics entering the market, prices are projected to decrease:
| Year |
Estimated Price per 1 mL Vial (USD) |
| 2024 |
$9 - $11 |
| 2025 |
$8.50 - $10.50 |
| 2026 |
$8 - $10 |
| 2027 |
$7.50 - $9.50 |
Assumptions include continued generic penetration, healthcare cost containment policies, and stable demand.
Regulatory and Reimbursement Factors
- FDA approval for glycopyrrolate injection remains unchanged.
- No recent label expansions or new indications.
- Reimbursement policies favor generic use, encouraging downward price pressure.
Competitive Dynamics
- Generics and biosimilars are likely to drive price reductions.
- Patent protections for the original drug expired years prior, increasing generic availability.
- Consolidation among suppliers could constrain pricing variability.
Strategic Implications
- Manufacturers can maintain margins by differentiating product quality, packaging, or formulation.
- Suppliers should monitor upcoming biosimilar entries for potential price erosion.
- Hospitals and procurement agencies should leverage generic options to reduce expenses.
Summary
Glycopyrrolate injection (NDC 60505-2521) operates in a stabilized market with consistent use in surgical and anesthetic settings. Prices are declining due to increased competition, with projected averages around $8-$10 per vial by 2027. Market growth remains moderate, driven by surgical volume rather than expanded indications.
Key Takeaways
- The market for glycopyrrolate injection is mature with evolving competition.
- Price declines are anticipated over the next five years, aligning with generic market trends.
- The overall market value is projected to grow at approximately 10% annually until 2027, driven by volume.
- Reimbursement landscapes favor generic adoption, influencing pricing strategies.
- Limited indications restrict rapid expansion but ensure steady demand.
FAQs
-
What factors influence the price of glycopyrrolate injection?
Price is affected by manufacturing costs, competition from generics, hospital procurement contracts, and reimbursement policies.
-
Are biosimilars likely to enter this market?**
No; glycopyrrolate is a small molecule, not a biologic, so biosimilars are not applicable. However, more generic competitors are entering.
-
What are the main off-label uses affecting the market?
Off-label uses include hyperhidrosis treatment and peptic ulcer management, but these are limited in scale.
-
How often do prices typically change?
Prices usually trend downward over time, especially as generics flood the market and hospital procurement strategies shift.
-
What risks could impact future prices?
Regulatory changes, patent disputes, or new formulations could alter price trajectories. Disruptions in hospital procurement policies may also influence volumes.
References
[1] IQVIA. (2022). Hospital and prescription drug sales data.
